[go: up one dir, main page]

MX2018007756A - Anticuerpos anti-cd20/anti-cd3 biespecificos para tratar leucemia linfoblastica aguda. - Google Patents

Anticuerpos anti-cd20/anti-cd3 biespecificos para tratar leucemia linfoblastica aguda.

Info

Publication number
MX2018007756A
MX2018007756A MX2018007756A MX2018007756A MX2018007756A MX 2018007756 A MX2018007756 A MX 2018007756A MX 2018007756 A MX2018007756 A MX 2018007756A MX 2018007756 A MX2018007756 A MX 2018007756A MX 2018007756 A MX2018007756 A MX 2018007756A
Authority
MX
Mexico
Prior art keywords
lymphoblastic leukemia
acute lymphoblastic
antibodies
treat acute
bispecific
Prior art date
Application number
MX2018007756A
Other languages
English (en)
Inventor
BROWNSTEIN Carrie
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2018007756A publication Critical patent/MX2018007756A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona métodos para tratar, reducir la gravedad o inhibir el crecimiento de la leucemia linfoblástica aguda. Los métodos de la presente invención comprenden administrar a un sujeto que lo necesita una cantidad terapéuticamente efectiva de un anticuerpo biespecífico que se une específicamente a CD20 y CD3.
MX2018007756A 2015-12-22 2016-12-21 Anticuerpos anti-cd20/anti-cd3 biespecificos para tratar leucemia linfoblastica aguda. MX2018007756A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562270749P 2015-12-22 2015-12-22
US201662306031P 2016-03-09 2016-03-09
PCT/US2016/068003 WO2017112762A1 (en) 2015-12-22 2016-12-21 Bispecific anti-cd20/anti-cd3 antibodies to treat acute lymphoblastic leukemia

Publications (1)

Publication Number Publication Date
MX2018007756A true MX2018007756A (es) 2018-08-09

Family

ID=57799832

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007756A MX2018007756A (es) 2015-12-22 2016-12-21 Anticuerpos anti-cd20/anti-cd3 biespecificos para tratar leucemia linfoblastica aguda.

Country Status (14)

Country Link
US (1) US20170174781A1 (es)
EP (1) EP3394102A1 (es)
JP (1) JP2019503363A (es)
KR (1) KR20180087401A (es)
CN (1) CN108602889A (es)
AU (1) AU2016378573A1 (es)
BR (1) BR112018012929A2 (es)
CA (1) CA3009322A1 (es)
EA (1) EA201891495A1 (es)
IL (1) IL260000A (es)
MA (1) MA44145A (es)
MX (1) MX2018007756A (es)
SG (1) SG11201805048SA (es)
WO (1) WO2017112762A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
AR102198A1 (es) 2014-10-09 2017-02-08 Regeneron Pharma Proceso para reducir partículas subvisibles en una formulación farmacéutica
ES2809455T3 (es) 2014-11-17 2021-03-04 Regeneron Pharma Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20
IL309453A (en) 2016-08-16 2024-02-01 Regeneron Pharma A method for quantifying individual antibodies from a mixture
IL289895B (en) 2016-10-25 2022-09-01 Regeneron Pharma Methods and systems for analysis of chromatography data
CA3073935A1 (en) 2017-09-19 2019-03-28 Regeneron Pharmaceuticals, Inc. Methods of reducing particle formation and compositions formed thereby
SG11202012405WA (en) * 2018-06-14 2021-01-28 Bioatla Inc Multi-specific antibody constructs
TW202448568A (zh) 2018-07-02 2024-12-16 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
US11157011B2 (en) * 2018-07-30 2021-10-26 Fedex Corporate Services, Inc. Enhanced systems, apparatus, and methods for improved automated and autonomous operation of logistics ground support equipment
HRP20250234T1 (hr) 2018-08-31 2025-04-11 Regeneron Pharmaceuticals, Inc. Strategija doziranja koja ublažava sindrom oslobađanja citokina za cd3/cd20 bispecifična antitijela
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CA3116717A1 (en) 2018-10-31 2020-05-07 Regeneron Pharmaceuticals, Inc. Method and system of identifying and quantifying a protein
US11249089B2 (en) 2018-12-12 2022-02-15 Regeneron Pharmaceuticals, Inc. System and method of analysis of a protein using liquid chromatography-mass spectrometry
US20200392230A1 (en) * 2019-05-14 2020-12-17 Qlb Biotherapeutics Bispecific anti-cd3 x cd20 antibodies and uses thereof
CN110498857B (zh) * 2019-08-09 2022-09-09 安徽瀚海博兴生物技术有限公司 一种抗vegf-抗pd1双特异性抗体
CN110563849B (zh) * 2019-08-09 2022-09-09 安徽瀚海博兴生物技术有限公司 一种抗vegf-抗pd1双特异性抗体
TW202128745A (zh) 2019-12-06 2021-08-01 美商再生元醫藥公司 抗ｖｅｇｆ蛋白組合物及其製備方法
TW202135860A (zh) * 2019-12-10 2021-10-01 美商再生元醫藥公司 含有抗ｃｄ２０ｘ抗ｃｄ３雙特異性抗體之穩定調配物
US12435154B2 (en) * 2020-05-08 2025-10-07 Genmab A/S Bispecific antibodies against CD3 and CD20
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
CN116322767A (zh) * 2020-06-04 2023-06-23 生物发明国际公司 改善与静脉内施用有关的抗体耐受性
CN112062855B (zh) 2020-08-26 2024-08-30 北京天诺健成医药科技有限公司 一种含有衔接器的药物治疗剂的开发和应用
US20230310599A1 (en) * 2020-09-02 2023-10-05 Genmab A/S Antibody therapy
CN114524878B (zh) 2020-11-23 2024-08-02 康诺亚生物医药科技（成都）有限公司 一种双特异性抗体及其用途
AR127271A1 (es) * 2021-10-09 2024-01-03 Hutchmed Ltd Anticuerpos biespecíficos que se unen específicamente a cd47 y cd20, y usos de los mismos
US20250076310A1 (en) 2022-12-08 2025-03-06 Regeneron Pharmaceuticals, Inc. Methods to characterizing a fragment crystallizable domain of a bispecific antibody
WO2025157132A1 (en) * 2024-01-23 2025-07-31 Wuxi Biologics (Shanghai) Co., Ltd. Multispecific antibodies targeting cd3, cd19 and cd20 and uses thereof
WO2025160324A2 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
WO2025160340A2 (en) * 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10307481B2 (en) * 2005-07-25 2019-06-04 Aptevo Research And Development Llc CD37 immunotherapeutics and uses thereof
US9382327B2 (en) * 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
HRP20150400T1 (hr) * 2008-11-07 2015-05-08 Amgen Research (Munich) Gmbh Lijeäśenje pedijatrijske akutne limfoblastiäśne leukemije
TWI754319B (zh) * 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物

Also Published As

Publication number Publication date
EA201891495A1 (ru) 2018-11-30
MA44145A (fr) 2018-10-31
US20170174781A1 (en) 2017-06-22
AU2016378573A1 (en) 2018-07-19
EP3394102A1 (en) 2018-10-31
WO2017112762A1 (en) 2017-06-29
IL260000A (en) 2018-07-31
BR112018012929A2 (pt) 2018-12-11
CN108602889A (zh) 2018-09-28
CA3009322A1 (en) 2017-06-29
SG11201805048SA (en) 2018-07-30
JP2019503363A (ja) 2019-02-07
KR20180087401A (ko) 2018-08-01

Similar Documents

Publication Publication Date Title
MX2018007756A (es) Anticuerpos anti-cd20/anti-cd3 biespecificos para tratar leucemia linfoblastica aguda.
MX2018007613A (es) Combinacion de anticuerpos anti proteina 1 de muerte celular (pd1) y anticuerpos anti grupo de diferenciacion 20 (cd20)/anti grupo de diferenciacion (cd3) biespecificos para tratar el cancer.
PH12020500075A1 (en) Checkpoint inhibitor bispecific antibodies
ZA201905051B (en) Anti-pd-1 antibodies for treatment of lung cancer
MX2017015811A (es) Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
MX2025008444A (es) Uso de un anticuerpo anti-pd-1 y un anticuerpo anti-cd3 x muc16 biespecifico para el tratamiento de un tumor que expresa muc16
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
ZA201701126B (en) Combination therapies with anti cd40 antibodies
SG10201901057UA (en) Anti-pd-l1 antibodies
EA201890162A1 (ru) Антитела к cd40 с повышенной агонистической активностью
EP3572430A3 (en) Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
EP3760229A3 (en) Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
NZ728688A (en) Anti-pd-1 antibodies
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
EP4609915A3 (en) Treatment of lung cancer using a combination of an anti-pd-1 antibody and an anti-ctla-4 antibody
MX2020008569A (es) Inhibidores selectivos de bcl-2 en combinacion con un anticuerpo anti-pd-1 o anti-pd-l1 para el tratamiento de tipos de cancer.
MX2014010987A (es) Tratamiento de esclerosis multiple con anticuerpo anti-cd19.
IL307821A (en) Dosage for treatment with BISPIFIC ANTI-CD20/ANTI-CD3 antibody
PH12019502313A1 (en) Anti-pd-l1-anti-tim-3 bispecific antibodies
MX2020006125A (es) Uso de un anticuerpo biespecifico de cea cd3 y un antagonista de la union al eje de pd-1 en un regimen de dosificacion para tratar el cancer.
MX2017003014A (es) Anticuerpos anti-alfa v beta 5 humanizados y usos de estos.
HK40006696A (en) Bispecific antibodies that bind cd20 and cd3 for use in the treatment of lymphoma
HK1262551A1 (en) Bispecific anti-cd20/anti-cd3 antibodies to treat acute lymphoblastic leukemia